No abstract available.
Budesonide* ; Humans

No abstract available.
Beclomethasone* ; Budesonide* ; Hydrocortisone*

PURPOSE: To evaluate the effect f nebulized budensonide and intramuscular dexamethasone in relieving laryngeal obstruction of croup. METHODS: Forty patients with moderate croup (croup scores of 3 to 7 out of 17) were randomly assigned to budesonide group [1 mg(2 ml) of nebulized budesonide, N=15], dexamethasone group [intramuscular dexamethasone(0.5 mg/kg) and nebulized saline, N=10] and control group(2 ml of nebulized saline, N=15). The changes of croup scores, heart rate, respiratory rate, and arterial oxygen saturation(SaO2) were observed at post-treatment of 2, 24, 36 and 48 hours. The duration of admission and the rates of improvement to the croup score of < or = 1 at the post-treatments were compared. RESULTS: Croup scores at 12, 24 and 36 hours post treatments were 1.7+/-0.8, 1.1+/-0.7 and 0.8+/-0.7 in budensonide group and 2.2+/-0.7, 1.2+/-0.8 and 1.0+/-0.5 in dexamethasone group respectively, which were significantly lower rate, and SaO2 were not significantly different among the three groups. Improved rates to croup score of <1 in budesonide group at post-treatments of 12, 24, and 36 jpirs were 53%, 73% and 87%, which were significantly higher than 0%, 13%, and 47% in control group (p<0.05). Improved rate to croup score of < or = 1 in dexamethasone group was 60^ which was significantly hgier than 13% in control group only at post-treatment of 24 hours (p<0.05). CONCLUSION: Nebulized budesonide and intramusculan dexamethasone are both effective in reducing obstructive symptoms in patients with moderate croup. The effect of nebulized budesonide was more rapid than that of intramuscular dexamethasone.
Budesonide* ; Croup ; Dexamethasone* ; Heart Rate ; Humans ; Oxygen ; Respiratory Rate

PURPOSE: Cough-variant asthma (CVA) is a common cause of chronic cough in young children. Some children who have CVA eventually develop classic asthma. We evaluated the effect of inhaled corticosteroid and leukotriene receptor antagonist in young children who are suspected of having CVA. METHODS: Thirty-seven cough-variant asthma patients younger than 5-years-old were enrolled in this study. Fifteen were treated with pulmicort nebulization (500 micorgram, bid) for 4 weeks (Group A). Fourteen were treated with leukotriene receptor antagonist (Singulair, 4 mg) for 4 weeks (Group B). Eleven were treated with intermittent short-acting beta2-agonist nebulization (Group C). We evaluated the mean change of symptom score in night cough and sleep disturbance. RESULTS: There were no differences in age, sex, total IgE, total eosinophil count or duration of cough among the three groups. Group A and B showed significant improvement of night cough and sleep disturbance after treatment. (P< 0.05) In Group A and B, night cough was significantly improved after treatment more than in control. (P< 0.05) But improvements in sleep disturbance didn't have any signigicant differences between the three groups. (P= 1.0) CONCLUSION: Inhaled corticosteroid and leukotriene receptor antagonist are effective to control chronic cough in CVA children younger than 5-years-old.
Asthma* ; Budesonide ; Child ; Cough ; Eosinophils ; Humans ; Immunoglobulin E ; Receptors, Leukotriene*

The aims of this study are to compare the efficacy and side effects of intranasal budesonide as a dry powder and as a freonpropelled pressurized aerosol in the treatment of perennial allergic rhinitis and to assess the difference in compliance with the powder and aerosol. The study design was a randomized, double-blind crossover between two treatment groups over a six-week period. Twelve patients with symptomatic perennial allergic rhinitis received 400 microgram of intranasal budesonide administered daily as two puffs/nostril/day of the drug delivered by a freon-propelled aerosol for the first three weeks and as one inhalation/nostril/day of the pure drug powder for the next three weeks. Fourteen adults with allergic rhinitis received the drug in the reverse sequence. Patients recorded daily symptoms on diaries, and, at each clinic visit, adverse effects were recorded. Compliance with the powder and with the aerosol was also evaluated. During the six weeks, there were significant improvements in symptoms in both treatment groups, and the differences in efficacy and compliance with the medication between the two groups were not significant. Adverse effects included headaches, epistaxis, and nasal dryness ; however, they were not serious and equally distributed in the two groups. We conclude that powder and aerosolized budesonide improve the symptoms of perennial allergic rhinitis significantly with little difference in efficacy, side effects, and preference.
Adult ; Ambulatory Care ; Budesonide* ; Compliance ; Epistaxis ; Headache ; Humans ; Rhinitis*

The aims of this study are to compare the efficacy and side effects of intranasal budesonide as a dry powder and as a freonpropelled pressurized aerosol in the treatment of perennial allergic rhinitis and to assess the difference in compliance with the powder and aerosol. The study design was a randomized, double-blind crossover between two treatment groups over a six-week period. Twelve patients with symptomatic perennial allergic rhinitis received 400 microgram of intranasal budesonide administered daily as two puffs/nostril/day of the drug delivered by a freon-propelled aerosol for the first three weeks and as one inhalation/nostril/day of the pure drug powder for the next three weeks. Fourteen adults with allergic rhinitis received the drug in the reverse sequence. Patients recorded daily symptoms on diaries, and, at each clinic visit, adverse effects were recorded. Compliance with the powder and with the aerosol was also evaluated. During the six weeks, there were significant improvements in symptoms in both treatment groups, and the differences in efficacy and compliance with the medication between the two groups were not significant. Adverse effects included headaches, epistaxis, and nasal dryness ; however, they were not serious and equally distributed in the two groups. We conclude that powder and aerosolized budesonide improve the symptoms of perennial allergic rhinitis significantly with little difference in efficacy, side effects, and preference.
Adult ; Ambulatory Care ; Budesonide* ; Compliance ; Epistaxis ; Headache ; Humans ; Rhinitis*

PURPOSE: This prospective study was conducted to evaulate the effect of nebulized steroid (budesonide) and parenteral steroid (dexamethasone) on chidren with croup. METHODS: Twenty nine infants and children (6months-5years of age) admitted to hospital with croup were randomly assigned to receive either 1mg (4ml) of nebulized budesonide (17 patients) or 0.6mg/kg intramuscular injection of dexamethasone sodium phosphate (12 patients). Total croup score, heart rate and respiratory rate of patients were assessed on admission, 30 minutes, 2 hours, 6 hours, 12 hours and 24 hours after treatment, respectively. RESULTS: 1) In total cases, total croup score were significantly decreased at 30 minutes after treatment in the group treated with nebulized budesonide (p<0.01) but at 2 hours after treatmetn in the group treated with dexamethasone (p<0.05). 2) In mild cases (total croup score<5), total croup score were significantly decreased at 2 hours after treatment in the both group (p<0.05). 3) In moderate to severe cases (total croup score> or =5), total croup score were significantly decreased at 30 minutes after treatment in the group treated with nebulized budesonide (p<0.05). But in group treated with dexamethasone, there were no statistical significance because of small cases. 4) Respiratory rate was decreased after treatment in the both group, but significantly decreased at 2 hours after treatment in the group treated with dexamethasone (p<0.05). 5) Heart rate was decreased after treatment in the both group, but significantly decreased at 30 minutes after treatment in the group treated with dexamethasone (p<0.05). 6) There were no significant side effects in the both group. CONCLUSIONS: We conclude that both nebulized budesonide and parenteral dexamethasone were effective in treatment of croup, and that nebulized budesonide leads to more rapid clinical improvement in children with croup, especially moderate to severe one.
Budesonide ; Child* ; Croup* ; Dexamethasone ; Heart Rate ; Humans ; Infant ; Injections, Intramuscular ; Prospective Studies ; Respiratory Rate ; Sodium

PURPOSE: Airways hyperresponsiveness is a hallmark of asthma. Inhaled corticosteroids improve hyperresponsiveness, but the extent of improvement may vary considerably between patients. This study was designed to determine which patient characteristics predict these differences in response. METHODS: Children with atopic asthma(n=71) received inhaled budesonide(800microgram per day) regularly for 12 weeks, and methacholine PC20 was measured before and after the treatment. Baseline clinical characteristics of children were analyzed with regard to their response to budesonide therapy. RESULTS: The children were divided into high(n=36) and low responder(n=35) on the basis of the median value of the doubling doses(change in PC20). There were no differences observed between the two groups with respect to age, sex, eosinophil counts, and pretreatment FEV1 or methacholine PC20. Among the allergic parameters, serum total IgE was higher in the high responder group than in the low responder group, whereas Dermatophagoides-specific IgE levels or skin test wheal sizes were not different between the two groups. There was a significant correlation between total IgE level and change in PC20. CONCLUSION: Total serum IgE was found to be the most important and single predictor of change in PC20 with inhaled corticosteroids.
Adrenal Cortex Hormones* ; Asthma ; Budesonide ; Child* ; Eosinophils ; Humans ; Immunoglobulin E* ; Methacholine Chloride ; Skin Tests

Nedocromil sodium is an anti-inflammatory medication for the treatment of mild to moderate asthma. The most common side effect of the nedocromil sodium is an unpleasant and bitter taste. However it is rare, less than 3%, to stop the treatment because of this side effect. Other side effects includes cough, headache, throat irritation and nausea which are reported as mild and transient. A 7-year-old female had a severe headache and dizziness during the treatment of asthma with nedocromil sodium. The symptoms subsided after nedocromil sodium was replaced by budesonide. We experienced a case of a severe headache and dizziness due to nedocomil sodium that lead to withdraw of the nedocromil sodium.
Asthma ; Budesonide ; Child ; Cough ; Dizziness* ; Female ; Headache* ; Humans ; Nausea ; Nedocromil* ; Pharynx ; Sodium

PURPOSE: Dexamethasone intramuscular injection and oral prednisolone have been known to be effective in the treatment of croup. The aim of this study was to determine whether nebulized budesonide leads to clinically important improvement in respiratory symptoms within four hours for child with mild to moderate croup. METHODS: Patients with croup visited to the department of Pediatrics, Han Il General Hospital from March 1995 to June 1996 were enrolled in this study. Patients were eligible if their age was between six months and six years, their total croup score was higher than 2 after breathing humidified air for at least 15 minutes. 28 patients were treated with 2mg (8ml) of nebulized budesonide and 8 patients with 8ml of normal saline as control group over the 30 minutes. Croup score, heart rate and respiratory rate were then assessed hourly for up to four hours. Side effects were also observed. RESULTS: 1) The croup score was improved from 3.6+/-0.8 to 1.9+/-0.9 at 4 hours after the nebulized budesonide treatment. 2) No significant differences in changes in heart rate were observed until 4 hours after both the nebulized budesonide group and control group. 3) Significant decrease in respiratory rate was observed at 4 hours after the nebulized budesonide group. 4) No specific side effects were noted during and 4 hours after the nebulized budesonide treatment. CONCLUSIONS: We concluded that nebulized budesonide leads to a prompt and important clinical improvement in children with mild to moderate croup without any specific side effects.
Budesonide* ; Child ; Croup* ; Dexamethasone ; Heart Rate ; Hospitals, General ; Humans ; Injections, Intramuscular ; Pediatrics ; Prednisolone ; Respiration ; Respiratory Rate